Inhibitor Therapeutics INTI
OTC INTI
$0.10 +0.00 (+0.00%)
At close: Sep 28, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Receivables - Other (2021)

Updated

Inhibitor Therapeutics (INTI) reported Receivables - Other of -$192,500 for Q3 2021.

Analysis

Inhibitor Therapeutics (INTI) Receivables - Other (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Inhibitor Therapeutics 17.38 Mn 17.38 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 -192,500.00
Jun 30, 2021 -134,750.00
Mar 31, 2021 -52,000.00
API Access

Inhibitor Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=INTI&period=max&api_key=YOUR_API_KEY